A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Switch From Daily Basal Insulin to Insulin Icodec in People Living With Type 2 Diabetes in Italy

The study will look at how well insulin icodec controls blood sugar levels in participants who have never used it before. Participants with type 2 diabetes (T2D) will be treated with insulin icodec as prescribed to by their doctor, in accordance with usual clinical practice. This study will last for about 22 to 30 weeks.

Start Date05 Jun 2026

Sponsor / Collaborator

Novo Nordisk A/S

NCT07591519

/ Not yet recruitingPhase 1

Evaluation of the Pharmacokinetics and Pharmacodynamics of IBI3035 and Awiqli? (Ecoporin Insulin Injection) in a Randomized, Open-label, Single-dose, Two-formulation, Crossover Design in Healthy Male Subjects in China: A Phase I Clinical Trial.

This study is a Phase I clinical trial that uses positive glucose clamping technology to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of IBI3035 with insulin injection (Awiqli?) after a single administration in healthy male subjects

Start Date08 May 2026

Sponsor / Collaborator

Innovent Biologics (Suzhou) Co. Ltd.

CTIS2025-521150-42-00

/ CompletedPhase 3

A 40-week study comparing the efficacy, safety and patient-reported outcomes of once weekly IcoSema and once or twice daily insulin degludec/insulin aspart 100 units/mL, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily pre-mixed insulin. COMBINE 5

Start Date02 Mar 2026

Sponsor / Collaborator

Novo Nordisk A/S

100 Clinical Results associated with Icodec Insulin

100 Translational Medicine associated with Icodec Insulin

100 Patents (Medical) associated with Icodec Insulin

122

Literatures (Medical) associated with Icodec Insulin

02 Jun 2026·Zhonghua yi xue za zhi

[Value and benefit of basic insulin/GLP-1RA weekly preparation in clinical treatment of type 2 diabetes in adults].

Article

Author: Zang, L ; Zhang, S C ; Cheng, Y ; Hu, X ; Mu, Y M

The prevalence of type 2 diabetes mellitus has been rising continuously in China. However, glycemic control rates remain suboptimal, posing a significant public health challenge. Although traditional intensive insulin strategies are effective in improving glycemic control, they are often associated with risks such as hypoglycemia and weight gain. Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) offer complementary mechanisms of action, enhancing efficacy and safety while simplifying treatment regimens, making them a key focus of clinical development. Insulin icodec/semaglutide fixed-ratio combination (IcoSema), the first once-weekly dual-component preparation combining a basal insulin and a GLP-1RA, utilizes advanced formulation technology to achieve stable co-formulation of the ultra-long-acting once-weekly basal insulin and the once-weekly GLP-1RA, with the two components acting in a complementary and synergistic manner. The Phase 3 COMBINE clinical trial program demonstrated that, compared with insulin icodec, semaglutide(1.0 mg), or basal-bolus insulin regimens, IcoSema provides superior or equivalent glycemic control, and the risk of clinically significant or severe hypoglycemic events is comparable to that of semaglutide(1.0 mg). Once-weekly administration helps to simplify the treatment regimen and improve treatment adherence. The clinical application of IcoSema is expected to alleviate the dilemma in Chinese type 2 diabetes management of balancing effective glycemic control with safety and simplicity, offering a new therapeutic option for patients requiring insulin intensification that combines efficacy, safety, and convenience.

01 Jun 2026·DIABETES OBESITY & METABOLISM

Early Real‐World Implementation of Once‐Weekly Insulin Icodec in Type 2 Diabetes

Letter

Author: La Vignera, Sandro ; Calogero, Aldo E. ; Condorelli, Rosita A. ; Randazzo, Rosario ; Cannarella, Rossella

03 May 2026·EXPERT OPINION ON PHARMACOTHERAPY

Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes

Review

Author: Desouza, Cyrus ; Batra, Jaskaran ; Ramachandran, Akshaya

INTRODUCTION:

This review summarizes current evidence on insulin efsitora alfa, a novel once-weekly basal insulin developed to simplify therapy in adults with diabetes. Its Fc-fusion molecular design enables a prolonged half-life and a flat pharmacokinetic profile with low variability. Data from the QWINT phase 3 program demonstrate non-inferior glycemic efficacy compared with once-daily basal insulins across type 2 diabetes populations. Reduced injection burden may improve adherence, satisfaction, and diabetes management.

AREAS COVERED:

This review discusses the molecular structure and pharmacokinetic mechanisms of insulin efsitora alfa, including insulin receptor binding and FcRn-mediated recycling responsible for its extended duration. Efficacy and safety outcomes from pivotal QWINT trials are reviewed, including HbA1c reduction, CGM outcomes, and hypoglycemia risk. Practical considerations such as dosing, titration, and benefits in real-world settings are highlighted. Evidence gaps remain for patients with advanced chronic kidney disease.

EXPERT OPINION:

Once-weekly insulins such as efsitora and icodec represent major advances in basal therapy. Efsitora's flatter profile may reduce peak-related hypoglycemia, with efficacy comparable to glargine or degludec. Severe hypoglycemia rates are low in type 2 diabetes and more safety data are needed in special populations.

News (Medical) associated with Icodec Insulin

27 May 2026

·www.novonordisk.com

Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions

Plainsboro, NJ, US and Bagsværd, Denmark, 27 May 2026 – Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association ® (ADA), taking place in New Orleans, June 5–8, 2026. Phase 3 REIMAGINE 1–3 results evaluating the effects of investigational CagriSema on glycemic control and weight loss across a range of type 2 diabetes background therapies will be featured in an ADA Scientific Session. 1 A total of 40 abstracts will be presented, including phase 2 data assessing the safety and efficacy of investigational once-weekly injectable zenagamtide, as well as new data for Ozempic ® and Wegovy ® , building on the growing body of clinical evidence for semaglutide across multiple cardiometabolic conditions. 2 “The ADA’s 2026 Scientific Sessions underscores the breadth and strength of our approach to cardiometabolic diseases. From amylin-based pipeline candidates to continued expansion of our portfolio, we are building on the established and unique profile of semaglutide,” said Martin Holst Lange, executive vice president of Research & Development and chief scientific officer at Novo Nordisk. “As pioneers in this space, we remain focused on advancing innovation that can meaningfully improve the lives of millions living with serious chronic diseases.” On Sunday, 7 June 2026, Novo Nordisk will host an R&D investor event on the science and abstracts presented at the conference. The event will be accessible via a live webcast on the Novo Nordisk investor website . Select Novo Nordisk abstracts to be presented at The ADA’s 2026 Scientific Sessions, 5-8 June, New Orleans: Data for investigational uses of semaglutide and investigational medicines containing CagriSema, zenagamtide, IcoSema, and efruxifermin. Symposium: • REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema – Sunday, 7 June; 4:30–6:00 pm CDT Novo Nordisk poster and oral presentations: CagriSema Zenagamtide Wegovy ® (semaglutide injection and tablets) Ozempic ® (semaglutide injection and tablets) Semaglutide for MASH Insulin Icodec • 1750-P Glucodynamics and Hypoglycemia Risk During Exercise or Fasting in Individuals with T2D Receiving Once-Weekly Basal Insulin Icodec – Saturday, 6 June; 12:30–1:30 pm CDT IcoSema Efruxifermin • 1294-OR Efruxifermin Improved Liver Disease and Insulin Sensitivity in Participants with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis in the SYMMETRY Trial – Monday, 8 June; 2:45–3:00 pm CDT Cross-product • 1696-P Effect of Semaglutide on COVID-19-Related Complications and All-Cause Death: Pooled Analyses of the SELECT, FLOW, and SOUL Trials – Sunday, 7 June; 12:30–1:30 pm CDT Non-product 9 additional abstracts being presented at ADA will cover data related to cardiometabolic diseases, including type 2 diabetes, obesity, kidney, and liver disease. CagriSema, zenagamtide, IcoSema, and efruxifermin are not approved in the United States. Safety and efficacy are not established, and there is no guarantee that these investigational medicines will become commercially available for the uses under clinical investigation. About semaglutide Semaglutide is a GLP-1 receptor agonist (GLP-1 RA) that is structurally similar to the naturally occurring hormone GLP-1. It works by selectively binding to and activating the GLP-1 receptor. Semaglutide has been tested in several robust clinical development programs and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease, and other related cardiometabolic diseases. Semaglutide is marketed under the brand names Wegovy ® (semaglutide) injection 2.4 mg, Wegovy ® HD (semaglutide) injection 7.2 mg, Wegovy ® (semaglutide) tablets 25 mg, Ozempic ® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, and Ozempic ® (semaglutide) tablets 4 mg or 9 mg. About CagriSema CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide. 1 About zenagamtide Zenagamtide, formerly known as amycretin, is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Zenagamtide is under investigation for oral and subcutaneous administration. About type 2 diabetes Type 2 diabetes is a chronic condition that affects how the body processes blood sugar (glucose) for energy. 3 According to 2023 CDC data, in the United States, 40.1 million people have diabetes, with type 2 diabetes representing 90% to 95%, or an estimated 36 – 38 million people living with type 2 diabetes, making it the most common form of the disease. 3,4 About obesity Obesity is a serious, chronic, progressive, and complex disease that requires long-term management. 5-7 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off. 5,7 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment. 8,9 About Novo Nordisk Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 67,900 people and markets products in roughly 170 countries. In the United States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in seven states plus Washington, D.C. For more information, visit novonordisk.com and novonordiskus.com, and follow us on Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information: References © 2026 Novo Nordisk All rights reserved. US26SEMO01000 May 2026

Phase 2Drug ApprovalPhase 3

06 May 2026

·www.biospace.com

Novo Nordisk’s adjusted operating profit reached DKK 32,858 million in Q1 2026

Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1 January 2026 to 31 March 2026 Financial performance Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US. Q1 2026 adjusted sales, excluding the 340B provision reversal, decreased by 4% at CER, driven by lower realised prices, partly offset by GLP-1 volume growth across geographies. Q1 2026 adjusted Obesity care sales increased by 22% at CER. US Operations adjusted sales decreased by 11% at CER in Q1 2026, driven by lower realised prices, partly offset by volume growth across the Wegovy ® product portfolio. International Operations sales increased by 6% at CER in Q1 2026, driven by higher volumes. Q1 2026 adjusted operating profit decreased by 6% at CER, while reported operating profit increased by 65% at CER, driven by a provision reversal related to the 340B Drug Pricing Program in the US. Commercial highlights Wegovy ® pill was launched in the US on 5 January 2026, and for the week ending 17 April, total weekly prescriptions exceeded 200,000. Coupled with total prescriptions for Q1 2026 of around 1.3 million and now more than 2 million since launch, it marks the strongest-ever GLP-1 volume launch in the US. Q1 2026 sales for Wegovy ® pill reached DKK 2,256 million, impacted by pre-launch pipeline fill with wholesalers and telehealth partners. Pending regulatory decisions, the first Wegovy ® pill launches outside the US are expected during the second half of 2026. Pipeline progress Within obesity, Wegovy ® HD (injectable semaglutide 7.2 mg) was approved by the FDA in March and subsequently launched in the US on 7 April. In the STEP UP trial, Wegovy ® HD provided 20.7% mean weight loss. Within obesity, the zenagamtide AMAZE phase 3 programme was initiated. Within diabetes, Awiqli ® , the first-ever once-weekly basal insulin for type 2 diabetes, was approved by the FDA. In sickle cell disease, etavopivat successfully met both co-primary endpoints in the HIBISCUS phase 3 trial. Outlook The 2026 outlook is raised, driven by increased expectations for GLP-1 product sales. Adjusted sales growth for 2026, which excludes the 340B provision reversal, is now expected to be -4 to -12% at CER. Adjusted operating profit growth, also excluding the 340B provision reversal, is now expected to be -4 to -12% at CER. PROFIT AND LOSS DKK million Q1 2026 Growth in DKK Growth at CER Net sales 96,823 24% 32% Operating profit 59,618 54% 65% Adjusted net sales 1 70,063 (10%) (4%) Adjusted operating profit 1 32,858 (15%) (6%) CER: Constant exchange rates; 1 Excl. USD 4.2 billion non-recurring impact from a provision reversal related to the 340B Drug Pricing Program in the US. Further details in Appendix 7 “Wegovy ® is driving a strong start to 2026 for Novo Nordisk, led by the rapid adoption of Wegovy ® pill - the most efficacious GLP-1 tablet now used by more than one million patients since its January launch. As the global momentum behind peptide-based therapies accelerates, Wegovy ® pill is defining a novel category as the only oral peptide for the treatment of obesity, setting a new benchmark for what patients and physicians can expect. The strong Wegovy ® performance, combined with continued growth in International Operations, has led us to raise our 2026 guidance for both adjusted sales and adjusted operating profit,” said Mike Doustdar, president and CEO of Novo Nordisk. “During the quarter, we also secured multiple approvals for Wegovy ® HD, strengthening the Wegovy ® portfolio, and enabling patients to achieve nearly 21% weight loss.” On 6 May 2026 at 13.00 CEST, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors' (the contents of the company's website do not form a part of this Form 6-K). A bout Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com Liz Skrbkova (US) +1 609 917 0632 usmediarelations@novonordisk.com Investors: Michael Novod +45 3075 6050 nvno@novonordisk.com Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com Max Ung +45 3077 6414 mxun@novonordisk.com Sina Meyer +45 3079 6656 azey@novonordisk.com Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com Alex Bruce +45 3444 2613 axeu@novonordisk.com Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com Company announcement No 30 / 2026 Attachment CA260506- Q1-2026

Phase 3Drug ApprovalClinical ResultFinancial StatementBiosimilar

01 Apr 2026

·allsci.com

Gan & Lee’s once-weekly basal insulin beats insulin glargine and degludec in Phase III type 2 diabetes trials

Gan & Lee Pharmaceuticals (SSE: 603087) reported that its investigational once-weekly basal insulin analog, GZR4, met the primary endpoint of superior HbA1c reduction versus both insulin glargine U100 (Lantus) and insulin degludec (Tresiba) across two pivotal Phase III trials in adults with type 2 diabetes, positioning the molecule as a direct challenger to Novo Nordisk’s recently FDA-approved insulin icodec (Awiqli). The SUPER-1 and SUPER-2 trials are active-controlled, treat-to-target Phase III studies enrolling 588 insulin-naïve and 631 basal-insulin-experienced Chinese adults with type 2 diabetes, respectively, conducted across more than 80 medical centers in China. In SUPER-1, the estimated mean HbA1c change from baseline at 26 weeks was -1.45% with GZR4 versus -1.22% with glargine U100, a between-group difference of -0.23%. In SUPER-2, GZR4 produced a -1.00% reduction compared with -0.58% for degludec, a difference of -0.42%. Both trials also showed GZR4 achieved a higher rate of the composite endpoint of HbA1c below 7.0% or at or below 6.5% without clinically significant or severe hypoglycemia. No severe (Level 3) hypoglycemic events occurred in either treatment group across both trials. GZR4 is an ultra-long-acting basal insulin analog engineered to provide full-week basal insulin coverage from a single subcutaneous injection, without requiring a loading dose. The absence of a loading dose distinguishes it from Awiqli, which requires a double maintenance dose in the first week to reach steady-state rapidly. The SUPER program describes a greater than 85% reduction in annual injection frequency compared with once-daily regimens — from approximately 365 injections per year to 52. The competitive context is acute. Novo Nordisk’s Awiqli received FDA approval for adults with type 2 diabetes on March 26, 2026 — five days before Gan & Lee released the SUPER-1 and SUPER-2 top-line data. Awiqli, which uses albumin binding to extend its half-life to approximately 196 hours, is now the only approved once-weekly basal insulin in the US market. GZR4 enters that comparison as an investigational molecule with Phase III superiority data versus daily analogs, but without head-to-head data against icodec yet available. That comparison is the subject of SUPER-8, a 26-week trial enrolling 300 patients with type 2 diabetes previously treated with basal insulin, with results expected within the next 12 months. Cross-trial comparisons are limited by differences in patient populations, titration algorithms, and background therapies. The magnitude of HbA1c separation in SUPER-2 — 0.42 percentage points versus degludec — is notable within the context of basal insulin trials, where active comparators are themselves well-optimized agents. The SUPER-1 difference of 0.23 percentage points versus glargine U100 is more modest, though both results met pre-specified superiority thresholds. Full statistical outputs, including confidence intervals and p-values, have not yet been disclosed; detailed results are planned for presentation at a scientific conference and peer-reviewed publication. The trials enrolled exclusively Chinese adults, which will be relevant to any regulatory filing strategy outside China. The SUPER program is described as a global Phase III development program, though the four currently initiated trials are all China-based. Whether Gan & Lee pursues regulatory submissions in the US or EU, and whether additional international trials are planned, was not addressed in the top-line release. Gan & Lee also has two additional SUPER trials underway: SUPER-3, enrolling 580 patients on basal-bolus therapy, comparing GZR4 against glargine U100 in combination with insulin aspart; and SUPER-8, the icodec head-to-head. The full dataset from all four trials will determine the breadth of the clinical package available for any regulatory submission. Detailed results from SUPER-1 and SUPER-2 are planned for presentation at a scientific conference later in 2026, with peer-reviewed publication to follow. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 3Clinical ResultDrug ApprovalPhase 2NDA

100 Deals associated with Icodec Insulin

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	Canada	Novo Nordisk Canada, Inc.	12 Mar 2024
Diabetes Mellitus, Type 2	Canada	Novo Nordisk Canada, Inc.	12 Mar 2024
Diabetes Mellitus	Switzerland	Novo Nordisk A/S	07 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05813912 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	148	Semaglutide+Insulin Icodec	zjvzrgmnbk(tkpfqwhynp) = nbmjcuvjbd tnwzrzpuxa (dydlfgrpkc, 0.86) View more	-	03 Jun 2026
NCT05823948 (ONWARDS 9, CTgov)	Phase 3	Diabetes Mellitus, Type 2	51	Insulin Icodec	cyczuhjmrh(dwweohdbrw) = dqicepqlrk odvlufmkjk (jticrlvqbf, 0.91) View more	-	30 Apr 2026
NCT04848480 (ONWARDS 6, Pubmed \| Diabetes Technol Ther)	Phase 3	Diabetes Mellitus, Type 1	246	Insulin Icodec	bwcqmlahtn(kkwkezkbsk) = Rates of CGM-based clinically significant hypoglycemic episodes (<3.0 mmol/L for ≥15 consecutive min) were statistically significantly higher with icodec than degludec from baseline to week 26 and week 57. tfrhpqteli (rtpupmcxun ) View more	Positive	01 Dec 2025
				Insulin Degludec
NCT05435677 (Pubmed \| Diabetes Ther)	Phase 1	Diabetes Mellitus, Type 2	20	IcoSema	dxhszqnysz(kgebjxcbnk): ratio = 1.04 (90.0% CI, 0.99 - 1.08) View more	Positive	06 Oct 2025
				icodec
NCT04760626 (ONWARDS 1-6 \| ONWARDS 1-5 \| ONWARDS 5, CTgov)	Phase 3	Diabetes Mellitus, Type 2	1,085	Insulin icodec (Insulin Icodec)	fijfinidnu(hlayfkttji) = dlumdhrwlp bdvpmrgggk (fwllechedt, 0.09) View more	-	26 Aug 2025
				Insulin (Once Daily Basal Insulin Analogue)	fijfinidnu(hlayfkttji) = vcmsfsdzmn bdvpmrgggk (fwllechedt, 0.12) View more
NCT04880850 \| NCT04770532 \| NCT04460885 \| NCT04795531 \| NCT04848480 \| NCT04760626 (ONWARDS 1-6, Pubmed \| Diabetes Ther)	Phase 3	-	-	Icodec	osufwzoocx(crijfpyxxz) = Mean HbA1c levels remained relatively stable over assessed time points for both treatment groups plopmnbccj (jfficdterr ) View more	Positive	01 Aug 2025
				Once-daily comparators (insulin degludec, insulin glargine U100, insulin glargine U300)
NCT04880850 (ONWARDS 1-6 \| ONWARDS 4 \| ONWARDS 1-5, CTgov)	Phase 3	Diabetes Mellitus, Type 2	582	insulin+Insulin icodec+insulin aspart (Insulin Icodec)	xyixoqruar(weafbrcdge) = hudpejwygm akyetxteuj (tmopocjuyy, 0.05) View more	-	02 Jul 2025
				Insulin Glargine (Insulin Glargine)	xyixoqruar(weafbrcdge) = tlsknsvvyk akyetxteuj (tmopocjuyy, 0.05) View more
NCT04460885 (ONWARDS 1-6 \| ONWARDS 1-5 \| ONWARDS 1, CTgov)	Phase 3	Diabetes Mellitus, Type 2	984	Insulin icodec (Insulin Icodec)	oqeeubzizm(tbmfibcwpy) = cidzucewol ontlfukirt (kfnsacvzdu, 0.06) View more	-	12 Jun 2025
				Insulin glargine (Insulin Glargine)	oqeeubzizm(tbmfibcwpy) = fjlzbuadql ontlfukirt (kfnsacvzdu, 0.05) View more
NCT04848480 (ONWARDS 6 \| ONWARDS 1-6, CTgov)	Phase 3	Diabetes Mellitus, Type 1	582	insulin icodec+insulin aspart (Insulin Icodec + Insulin Aspart)	zixeidsljp(bucmrbdiyq) = hewvxqudwe ihtbjglrzw (rrqpkeygkt, 0.07) View more	-	12 Jun 2025
				insulin degludec+insulin aspart (Insulin Degludec + Insulin Aspart)	zixeidsljp(bucmrbdiyq) = xtcnlslphy ihtbjglrzw (rrqpkeygkt, 0.06) View more
NCT05823948 (ONWARDS 9, Pubmed \| Diabetes Technol Ther \| NEWS) Manual	Phase 3	Diabetes Mellitus, Type 2	51	Once-weekly Insulin Icodec	irbquaajzd(mfmzrospbz) = tkswcnsuua rkqfwidfre (vjsjrcorqp, -1.36 to -0.99)	Positive	05 Mar 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis